The Freedom to Heal Act of 2025 aims to create a special registration process for physicians who want to administer certain investigational drugs classified as schedule I under the Controlled Substances Act. This law is designed to facilitate access to these drugs for patients who are eligible under the Federal Right to Try law, which allows patients with serious conditions to try experimental treatments that have not yet received full FDA approval. The key provisions of this law include a defined process for physicians to apply for registration to administer these investigational drugs.